Merck Archives

Promotional graphic for Tribe Public’s Eupraxia Pharmaceuticals webinar, “Food Shouldn’t Hurt: Why Eupraxia Pharmaceuticals Is Building a More Precise EoE Investment Story,” featuring CEO James Helliwell, MD; EoE inflammation imagery, precision-healing graphics and event details for Friday, August 21, 2026.

Food Shouldn’t Hurt: Why Eupraxia Pharmaceuticals Is Building a More Precise EoE Investment Story -( $EPRX $MRNA $MRK $REGN $SNY $TAK $XBI )

by John F. Heerdink, Jr. August 21, 2026 269Views 0Likes

Tribe Public CEO Presentation & Q&A: Hosted Friday, August 21 Tribe Public hosted its CEO Presentation and Q&A webinar, “Food Shouldn’t Hurt: EOE, Eupraxia, and a Promising New Treatment Approach,” featuring James Helliwell, MD, Chief Executive Officer of Eupraxia Pharmaceuticals Inc. (NASDAQ:…

Moderna’s Melanoma Momentum Rekindles the mRNA Growth Story—and Keeps Biotech Investors Hunting for Precision -( $EPRX $XBI $MRK $MRNA )

by John F. Heerdink, Jr. August 19, 2026 298Views 0Likes

The biotechnology market has a habit of demanding patience right up until it abruptly decides to reward it. Moderna, Inc. (NASDAQ: MRNA) recently reminded investors of that rule as enthusiasm around its personalized melanoma-vaccine program with Merck & Co., Inc. (NYSE: MRK)…

Atlanta Joins the Ebola Watchlist: How One Airport and One Biotech Are Keeping Calm and Carrying On -( $DAL $GOVX $XBI )

by John F. Heerdink, Jr. May 24, 2026 376Views 0Likes

The United States is quietly tightening its Ebola defenses, and this time Atlanta’s massive air hub and a small vaccine developer based in Atlanta named GeoVax Labs (NASDAQ: GOVX) are sharing the spotlight in a story that is more about preparedness than…

From Viral Load to Order Book: What the Congo Ebola Outbreak Could Mean for Vaccine Names -( $MRK $JNJ $GOVX )

by John F. Heerdink, Jr. May 18, 2026 389Views 0Likes

A new Ebola outbreak in Congo is once again testing global health systems, but it is also spotlighting a small group of vaccine developers who have spent the quiet years preparing for noisy ones like this. As health agencies scramble on the…

FDA Musical Chairs: What the Latest Leadership Shuffle Means for Biotech Investors -( $IBB $XBI )

by John F. Heerdink, Jr. May 16, 2026 430Views 0Likes

The FDA’s latest reshuffle of its top drug and biologics leaders lands biotech in yet another plot twist—but this one may read more like a quirky chapter break than a full-blown cliffhanger for investors. FDA’s New Cast at the Top The Food…

Family Offices Put On The White Coat: Why The Smart Money Is Suddenly Fluent In AI & Oncology

by John F. Heerdink, Jr. May 12, 2026 419Views 0Likes

Family offices didn’t just come back to the deal table in April – they showed up with term sheets in one hand and stethoscopes in the other. Healthcare Becomes the New Family Office Heirloom After a cautious March tied to geopolitical jitters…

From Molecules to Millions: How Eupraxia, Eli Lilly and Merck Navigate the FDA Maze -( $EPRX $LLY $MRK )

by John F. Heerdink, Jr. May 4, 2026 364Views 0Likes

The modern FDA approval maze is becoming less a straight corridor and more a high-speed roundabout—and investors riding with Eupraxia Pharmaceuticals (EPRX), Eli Lilly (LLY) and Merck (MRK) may find that’s exactly where outsized opportunity lives. From Wall Poster to Wall Street…

Acquired Taste: Why Big Pharma Can’t Stop Snacking on Venture‑Backed Biotechs -( $IBB $MRK $OTSKY $NVS $TERN $XBI )

by John F. Heerdink, Jr. April 2, 2026 463Views 0Likes

Big Pharma spent the week shopping again, snapping up a fresh crop of biotech and pharmaceutical names in deals that underscore one message: pipelines are the new gold, and the majors are still happily paying spot prices. From autoimmune bets to allergy…

Merck’s Nearly $6 Billion Terns Buyout Deal Signals Big Pharma’s Next Act in Cancer—and Obesity? -( $MRK $TERN $LLY $NVS $IBB $XBI )

by John F. Heerdink, Jr. March 25, 2026 693Views 0Likes

Merck (MRK) is preparing to spend nearly $6 billion in cash to acquire Terns Pharmaceuticals (TERN), a move that reads like a carefully scripted sequel to its Keytruda blockbuster rather than an impulsive spin-off. The price represents a premium to Terns’ roughly…

New York’s First Severe Mpox Case Arrives – And So Does a New Chapter for Preparedness -( $GOVX $IBB $XBI )

by John F. Heerdink, Jr. March 16, 2026 327Views 0Likes

New York City woke up this week to a headline it doesn’t particularly enjoy: its first documented case of severe mpox, specifically the clade I strain associated with more serious disease and higher mortality. Health officials confirmed that the patient had recently…

Merck

Your Guide To Staying Informed In The Markets